Skip to content
OpenCapital
Get started

Edgewise Therapeutics, Inc. EWTX Cash ratio

Cash ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Cytokinetics logo
CytokineticsCYTK
0.7×+0.2×
PTC Therapeutics logo
PTC TherapeuticsPTCT
0.9×-1.6×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
5.7×+0.5×
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
14.7×+0.8×
Viking Therapeutics logo
Viking TherapeuticsVKTX
1.1×-0.8×

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$3.96B+61.3%
Enterprise value$3.93B+63.5%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0×0.0×
Current ratio22.6×+1.6×

Where this comes from

Calculated from Edgewise Therapeutics, Inc.’s reported figures.

cash and equivalents/total current liabilities=1.5×

Based on the most recent quarter.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s cash ratio?
Edgewise Therapeutics, Inc. (EWTX) reported cash ratio of 1.5× in Q1 2026.
How has Edgewise Therapeutics, Inc.'s cash ratio changed year-over-year?
Edgewise Therapeutics, Inc.'s cash ratio decreased by 37.7% year-over-year, from 2.4× to 1.5×.
What is the long-term trend for Edgewise Therapeutics, Inc.'s cash ratio?
Over 5 years (2020 to 2025), Edgewise Therapeutics, Inc.'s cash ratio has grown at a -37.9% compound annual growth rate (CAGR), from 24.2× to 2.2×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.